A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Conditions:   Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor;   Hemophilia A Intervention:   Drug: Emicizumab Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials